This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Russia's International Biotechnology Center Generium Signs Access Agreement To Elsevier's ScienceDirect And Embase

Stocks in this article: ENLRENRUK

MOSCOW, October 31, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Russia's International Biotechnology Center (IBC) Generium, has signed an agreement to grant access to ScienceDirect and Embase for its scientists.

Access to ScienceDirect, Elsevier's full-text platform for scientific, technical and medical research literature and Embase, the most comprehensive international database for biomedical researchers, supports the company's strategy to maintain its leading position in Russia in generic drug development and innovate in biotechnological therapies.

Established in 2011, Generium has a unique and extensive portfolio of innovative drugs and biotechnological therapies. Generium's aim is to innovate in biotechnological therapies against diseases such as oncology as well as cardio-vascular, neurodegenerative and autoimmune disorders. The center's research and development teams will benefit greatly from its newly acquired access to ScienceDirect and Embase, by providing them with peer-reviewed full-text research papers published in more than 2000 international journals, as well as timely access to biomedical information.

Dr. Andrei Petrov, Chief Scientific Officer of Generium, said, "We are delighted to reach this agreement with Elsevier providing our research and development teams with online access to an extensive stream of world-class scientific content which will substantially facilitate our own research on drug discovery and development. We consider both ScienceDirect and Embase as critical tools for strengthening our competitive position."

Igor Osipov, PhD, Elsevier Regional Director for Russia and Belarus said, "We are honored to work with Generium, marking our first collaboration within the corporate market for biotechnology in Russia. We are confident that access to ScienceDirect and Embase will help Generium to continuously innovate and expand their line of products."

About Generium

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs